Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer Immunology, Immunotherapy
Published in: Cancer Immunology, Immunotherapy 7/2013

01-07-2013 | Original Article

Analysis of surrogate gene expression markers in peripheral blood of melanoma patients to predict treatment outcome of adjuvant pegylated interferon alpha 2b (EORTC 18991 side study)

Authors: Antonia Busse, Jérôme Rapion, Alberto Fusi, Stefan Suciu, Anika Nonnenmacher, Mario Santinami, Wim H. J. Kruit, Alessandro Testori, Cornelis J. A. Punt, Angus G. Dalgleish, Alan Spatz, Alexander M. M. Eggermont, Ulrich Keilholz

Published in: Cancer Immunology, Immunotherapy | Issue 7/2013

Login to get access

Abstract

We analysed mRNA levels of interferon response genes (ISG15, STAT1, CXCL10) of inhibitors of the JAK/STAT pathway (STAT3, SOCS1, SOCS3) and of cytokines (TNFα, IL10, TGFß1) in peripheral blood of 91 stage III melanoma patients enrolled in EORTC 18991 trial to find biomarkers indicative for disease stage and predictive for efficacy of pegylated interferon alpha-2b (PEG-IFNα-2b) therapy. mRNA levels were analysed at baseline and after 6 months. Univariate and multivariate analyses were performed to estimate the prognostic and predictive role of mRNA levels for distant metastasis-free survival (DMFS) and relapse-free survival (RFS). Compared to healthy controls, melanoma patients showed significantly higher TGFβ1 mRNA levels. In a multivariate model, increasing SOCS1 and SOCS3 mRNA levels were associated with worse RFS (P = 0.02 and P = 0.04, respectively) and DMFS (P = 0.05 and P = 0.05, respectively) due to negative correlation between, respectively, SOCS1/SOCS3 mRNA levels and ulceration or Breslow thickness. No impact of PEG-IFNα-2b on mRNA levels was observed except for ISG15 mRNA levels, which decreased in the treatment arm (P = 0.001). It seems that patients with a decrease >60 % of ISG15 mRNA levels during 6 months PEG-IFNα-2b had inferior outcome.
Literature
1.
Wheatley K, Ives N, Hancock B, Gore M, Eggermont A, Suciu S (2003) Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials. Cancer Treat Rev 29(4):241–252PubMedCrossRef
2.
Kirkwood JM, Manola J, Ibrahim J, Sondak V, Ernstoff MS, Rao U (2004) A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res 10(5):1670–1677PubMedCrossRef
3.
Eggermont AM, Suciu S, Santinami M, Testori A, Kruit WH, Marsden J, Punt CJ, Sales F, Gore M, Mackie R, Kusic Z, Dummer R, Hauschild A, Musat E, Spatz A, Keilholz U (2008) Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet 372(9633):117–126PubMedCrossRef
4.
Anaya DA, Xing Y, Feng L, Huang X, Camacho LH, Ross MI, Gershenwald JE, Lee JE, Mansfield PF, Cormier JN (2008) Adjuvant high-dose interferon for cutaneous melanoma is most beneficial for patients with early stage III disease. Cancer 112(9):2030–2037PubMedCrossRef
5.
Eggermont AM, Suciu S, MacKie R, Ruka W, Testori A, Kruit W, Punt CJ, Delauney M, Sales F, Groenewegen G, Ruiter DJ, Jagiello I, Stoitchkov K, Keilholz U, Lienard D (2005) Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial. Lancet 366(9492):1189–1196PubMedCrossRef
6.
Eggermont AM, Suciu S, Testori A, Kruit WH, Marsden J, Punt CJ, Santinami M, Sales F, Schadendorf D, Patel P, Dummer R, Robert C, Keilholz U, Yver A, Spatz A (2012) Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991. Eur J Cancer 48(2):218–225PubMedCrossRef
7.
McMasters KM, Edwards MJ, Ross MI, Reintgen DS, Martin RC, 2nd, Urist MM, Noyes RD, Sussman JJ, Stromberg AJ, Scoggins CR (2010) Ulceration as a predictive marker for response to adjuvant interferon therapy in melanoma. Ann Surg 252(3):460–465; discussion 465–466
8.
Wheatley KIN, Eggermont A (2007) Interferon-α as adjuvant therapy for melanoma: an individual patient data meta-analysis of randomised trials. ASCO Annual Meeting Proceedings Part 1. J Clin Oncol 25(suppl 18S):abstract 8526
9.
Ferrantini M, Capone I, Belardelli F (2007) Interferon-alpha and cancer: mechanisms of action and new perspectives of clinical use. Biochimie 89(6–7):884–893PubMedCrossRef
10.
Lesinski GB, Anghelina M, Zimmerer J, Bakalakos T, Badgwell B, Parihar R, Hu Y, Becknell B, Abood G, Chaudhury AR, Magro C, Durbin J, Carson WE 3rd (2003) The antitumor effects of IFN-alpha are abrogated in a STAT1-deficient mouse. J Clin Investig 112(2):170–180PubMed
11.
Badgwell B, Lesinski GB, Magro C, Abood G, Skaf A, Carson W 3rd (2004) The antitumor effects of interferon-alpha are maintained in mice challenged with a STAT1-deficient murine melanoma cell line. J Surg Res 116(1):129–136PubMedCrossRef
12.
Astsaturov I, Petrella T, Bagriacik EU, de Benedette M, Uger R, Lumber G, Berinstein N, Elias I, Iscoe N, Hammond C, Hamilton P, Spaner DE (2003) Amplification of virus-induced antimelanoma T-cell reactivity by high-dose interferon-alpha2b: implications for cancer vaccines. Clin Cancer Res 9(12):4347–4355PubMed
13.
Ascierto PA, Kirkwood JM (2008) Adjuvant therapy of melanoma with interferon: lessons of the past decade. J Transl Med 6:62PubMedCrossRef
14.
Gogas H, Ioannovich J, Dafni U, Stavropoulou-Giokas C, Frangia K, Tsoutsos D, Panagiotou P, Polyzos A, Papadopoulos O, Stratigos A, Markopoulos C, Bafaloukos D, Pectasides D, Fountzilas G, Kirkwood JM (2006) Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 354(7):709–718PubMedCrossRef
15.
Moschos SJ, Edington HD, Land SR, Rao UN, Jukic D, Shipe-Spotloe J, Kirkwood JM (2006) Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses. J Clin Oncol 24(19):3164–3171PubMedCrossRef
16.
Critchley-Thorne RJ, Yan N, Nacu S, Weber J, Holmes SP, Lee PP (2007) Down-regulation of the interferon signaling pathway in T lymphocytes from patients with metastatic melanoma. PLoS Med 4(5):e176PubMedCrossRef
17.
Lesinski GB, Kondadasula SV, Crespin T, Shen L, Kendra K, Walker M, Carson WE 3rd (2004) Multiparametric flow cytometric analysis of inter-patient variation in STAT1 phosphorylation following interferon Alfa immunotherapy. J Natl Cancer Inst 96(17):1331–1342PubMedCrossRef
18.
Schindler C, Plumlee C (2008) Inteferons pen the JAK-STAT pathway. Semin Cell Dev Biol 19(4):311–318PubMedCrossRef
19.
Theofilopoulos AN, Baccala R, Beutler B, Kono DH (2005) Type I interferons (alpha/beta) in immunity and autoimmunity. Annu Rev Immunol 23:307–336PubMedCrossRef
20.
Dalpke A, Heeg K, Bartz H, Baetz A (2008) Regulation of innate immunity by suppressor of cytokine signaling (SOCS) proteins. Immunobiology 213(3–4):225–235PubMedCrossRef
21.
Zimmerer JM, Lesinski GB, Kondadasula SV, Karpa VI, Lehman A, Raychaudhury A, Becknell B, Carson WE 3rd (2007) IFN-alpha-induced signal transduction, gene expression, and antitumor activity of immune effector cells are negatively regulated by suppressor of cytokine signaling proteins. J Immunol 178(8):4832–4845PubMed
22.
Ito S, Ansari P, Sakatsume M, Dickensheets H, Vazquez N, Donnelly RP, Larner AC, Finbloom DS (1999) Interleukin-10 inhibits expression of both interferon alpha- and interferon gamma- induced genes by suppressing tyrosine phosphorylation of STAT1. Blood 93(5):1456–1463PubMed
23.
Cassatella MA, Gasperini S, Bovolenta C, Calzetti F, Vollebregt M, Scapini P, Marchi M, Suzuki R, Suzuki A, Yoshimura A (1999) Interleukin-10 (IL-10) selectively enhances CIS3/SOCS3 mRNA expression in human neutrophils: evidence for an IL-10-induced pathway that is independent of STAT protein activation. Blood 94(8):2880–2889PubMed
24.
Park IK, Shultz LD, Letterio JJ, Gorham JD (2005) TGF-beta1 inhibits T-bet induction by IFN-gamma in murine CD4 + T cells through the protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-1. J Immunol 175(9):5666–5674PubMed
25.
Fox SW, Haque SJ, Lovibond AC, Chambers TJ (2003) The possible role of TGF-beta-induced suppressors of cytokine signaling expression in osteoclast/macrophage lineage commitment in vitro. J Immunol 170(7):3679–3687PubMed
26.
Brassard DL, Delorenzo MM, Cox S, Leaman DW, Sun Y, Ding W, Gavor S, Spond J, Goodsaid F, Bordens R, Grace MJ (2004) Regulation of gene expression by pegylated IFN-alpha2b and IFN-alpha2b in human peripheral blood mononuclear cells. J Interferon Cytokine Res 24(8):455–469PubMedCrossRef
27.
Taylor MW, Tsukahara T, Brodsky L, Schaley J, Sanda C, Stephens MJ, McClintick JN, Edenberg HJ, Li L, Tavis JE, Howell C, Belle SH (2007) Changes in gene expression during pegylated interferon and ribavirin therapy of chronic hepatitis C virus distinguish responders from nonresponders to antiviral therapy. J Virol 81(7):3391–3401PubMedCrossRef
28.
Zimmerer JM, Lehman AM, Ruppert AS, Noble CW, Olencki T, Walker MJ, Kendra K, Carson WE 3rd (2008) IFN-alpha-2b-induced signal transduction and gene regulation in patient peripheral blood mononuclear cells is not enhanced by a dose increase from 5 to 10 mega units/m2. Clin Cancer Res 14(5):1438–1445PubMedCrossRef
29.
Keilholz U, Goldin-Lang P, Bechrakis NE, Max N, Letsch A, Schmittel A, Scheibenbogen C, Heufelder K, Eggermont A, Thiel E (2004) Quantitative detection of circulating tumor cells in cutaneous and ocular melanoma and quality assessment by real-time reverse transcriptase-polymerase chain reaction. Clin Cancer Res 10(5):1605–1612PubMedCrossRef
30.
Bouwhuis MG, Suciu S, Collette S, Aamdal S, Kruit WH, Bastholt L, Stierner U, Sales F, Patel P, Punt CJ, Hernberg M, Spatz A, ten Hagen TL, Hansson J, Eggermont AM (2009) Autoimmune antibodies and recurrence-free interval in melanoma patients treated with adjuvant interferon. J Natl Cancer Inst 101(12):869–877PubMedCrossRef
31.
Bouwhuis MG, Suciu S, Testori A, Kruit WH, Sales F, Patel P, Punt CJ, Santinami M, Spatz A, Ten Hagen TL, Eggermont AM (2010) Phase III trial comparing adjuvant treatment with pegylated interferon Alfa-2b versus observation: prognostic significance of autoantibodies–EORTC 18991. J Clin Oncol 28(14):2460–2466PubMedCrossRef
32.
Bouwhuis MG, Suciu S, Kruit W, Sales F, Stoitchkov K, Patel P, Cocquyt V, Thomas J, Lienard D, Eggermont AM, Ghanem G (2011) Prognostic value of serial blood S100B determinations in stage IIB-III melanoma patients: a corollary study to EORTC trial 18952. Eur J Cancer 47(3):361–368PubMedCrossRef
33.
Bouwhuis MG, Collette S, Suciu S, de Groot ER, Kruit WH, Ten Hagen TL, Aarden LA, Eggermont AM, Swaak AJ (2011) Changes of ferritin and CRP levels in melanoma patients treated with adjuvant interferon-alpha (EORTC 18952) and prognostic value on treatment outcome. Melanoma Res 21(4):344–351PubMedCrossRef
34.
Guenterberg KD, Lesinski GB, Mundy-Bosse BL, Karpa VI, Jaime-Ramirez AC, Wei L, Carson WE 3rd (2011) Enhanced anti-tumor activity of interferon-alpha in SOCS1-deficient mice is mediated by CD4(+) and CD8(+) T cells. Cancer Immunol Immunother 60(9):1281–1288PubMedCrossRef
35.
Ascierto PA, Napolitano M, Celentano E, Simeone E, Gentilcore G, Daponte A, Capone M, Caraco C, Calemma R, Beneduce G, Cerrone M, De Rosa V, Palmieri G, Castello G, Kirkwood JM, Marincola FM, Mozzillo N (2010) Regulatory T cell frequency in patients with melanoma with different disease stage and course, and modulating effects of high-dose interferon-alpha 2b treatment. J Transl Med 8:76PubMedCrossRef
36.
Cesana GC, DeRaffele G, Cohen S, Moroziewicz D, Mitcham J, Stoutenburg J, Cheung K, Hesdorffer C, Kim-Schulze S, Kaufman HL (2006) Characterization of CD4 + CD25 + regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. J Clin Oncol 24(7):1169–1177PubMedCrossRef
37.
Elliott B, Scolyer RA, Suciu S, Lebecque S, Rimoldi D, Gugerli O, Musat E, Sharma RN, Lienard D, Keilholz U, Testori A, Eggermont A, MacKie R, Robert C, Cook M, Thompson JF, Angevin E, Spatz A (2007) Long-term protective effect of mature DC-LAMP + dendritic cell accumulation in sentinel lymph nodes containing micrometastatic melanoma. Clin Cancer Res 13(13):3825–3830PubMedCrossRef
38.
Yurkovetsky ZR, Kirkwood JM, Edington HD, Marrangoni AM, Velikokhatnaya L, Winans MT, Gorelik E, Lokshin AE (2007) Multiplex analysis of serum cytokines in melanoma patients treated with interferon-alpha2b. Clin Cancer Res 13(8):2422–2428PubMedCrossRef
39.
Worschech A, Kmieciak M, Knutson KL, Bear HD, Szalay AA, Wang E, Marincola FM, Manjili MH (2008) Signatures associated with rejection or recurrence in HER-2/neu-positive mammary tumors. Cancer Res 68(7):2436–2446PubMedCrossRef
40.
Huang FJ, Steeg PS, Price JE, Chiu WT, Chou PC, Xie K, Sawaya R, Huang S (2008) Molecular basis for the critical role of suppressor of cytokine signaling-1 in melanoma brain metastasis. Cancer Res 68(23):9634–9642PubMedCrossRef
41.
Gogas H, Paterakis G, Frangia K, Bafaloukos D, Pectasides D, Kalofonos HP, Loukopoulos D, Stavropoulou-Giokas C, Ioannovich J, Mihm MC Jr (2002) Lymphocyte subpopulations and interleukin levels in high-risk melanoma patients treated with high-dose interferon A-2B. Am J Clin Oncol 25(6):591–596PubMedCrossRef
42.
Simons DL, Lee G, Kirkwood JM, Lee PP (2011) Interferon signaling patterns in peripheral blood lymphocytes may predict clinical outcome after high-dose interferon therapy in melanoma patients. J Transl Med 5(9):52–60CrossRef
43.
Malakhov MP, Kim KI, Malakhova OA, Jacobs BS, Borden EC, Zhang DE (2003) High-throughput immunoblotting. Ubiquitin-like protein ISG15 modifies key regulators of signal transduction. J Biol Chem 278(19):16608–16613PubMedCrossRef
44.
Shi HX, Yang K, Liu X, Liu XY, Wei B, Shan YF, Zhu LH, Wang C (2010) Positive regulation of interferon regulatory factor 3 activation by Herc5 via ISG15 modification. Mol Cell Biol 30(10):2424–2436PubMedCrossRef
45.
Malakhova OA, Yan M, Malakhov MP, Yuan Y, Ritchie KJ, Kim KI, Peterson LF, Shuai K, Zhang DE (2003) Protein ISGylation modulates the JAK-STAT signaling pathway. Genes Dev 17(4):455–460PubMedCrossRef
46.
Chen L, Borozan I, Sun J, Guindi M, Fischer S, Feld J, Anand N, Heathcote J, Edwards AM, McGilvray ID (2010) Cell-type specific gene expression signature in liver underlies response to interferon therapy in chronic hepatitis C infection. Gastroenterology 138(3):1123–1133, e1121–e1123
Metadata
Title
Analysis of surrogate gene expression markers in peripheral blood of melanoma patients to predict treatment outcome of adjuvant pegylated interferon alpha 2b (EORTC 18991 side study)
Authors
Antonia Busse
Jérôme Rapion
Alberto Fusi
Stefan Suciu
Anika Nonnenmacher
Mario Santinami
Wim H. J. Kruit
Alessandro Testori
Cornelis J. A. Punt
Angus G. Dalgleish
Alan Spatz
Alexander M. M. Eggermont
Ulrich Keilholz
Publication date
01-07-2013
Publisher
Springer-Verlag
Published in
Cancer Immunology, Immunotherapy / Issue 7/2013
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-013-1428-4

Other articles of this Issue 7/2013

Cancer Immunology, Immunotherapy 7/2013 Go to the issue

Original Article

Intratumoral injection of therapeutic HPV vaccinia vaccine following cisplatin enhances HPV-specific antitumor effects

Original Article

Therapy model for advanced intracerebral B16 mouse melanoma using radiation therapy combined with immunotherapy

Original Article

Ex vivo analysis of pancreatic cancer-infiltrating T lymphocytes reveals that ENO-specific Tregs accumulate in tumor tissue and inhibit Th1/Th17 effector cell functions

Original Article

Anti-metastatic potential of human Vδ1+ γδ T cells in an orthotopic mouse xenograft model of colon carcinoma

Original Article

EBV-transformed lymphoblastoid cell lines as vaccines against cancer testis antigen-positive tumors

Original Article

Activation, dysfunction and retention of T cells in vaccine sites after injection of incomplete Freund’s adjuvant, with or without peptide
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits